|Systematic (IUPAC) name|
|Metabolism||Hepatic cytochrome P-450 oxygenase system|
|Biological half-life||18 hours|
|CAS Registry Number|
|ATC code||P03 QP53 QS02|
|Molecular mass||290.83 g/mol|
Lindane, also known as gamma-hexachlorocyclohexane, (γ-HCH), gammaxene, Gammallin and sometimes incorrectly called hexachlorocyclohexane that has been used both as an agricultural insecticide and as a pharmaceutical treatment for lice and scabies.
Lindane is a neurotoxin that interferes with GABA neurotransmitter function by interacting with the GABAA receptor-chloride channel complex at the picrotoxin binding site. In humans, lindane affects the nervous system, liver and kidneys, and may be a carcinogen. It is unclear whether lindane is an endocrine disruptor.
History and use 1
United States 1.1
- Pharmaceutical uses 1.1.1
- Morton Grove lawsuit 1.1.2
- United States 1.1
Human health effects 2
- Cancer risk 2.1
- Endometriosis risk 2.2
- Adverse reactions to lindane 2.3
Environmental contamination 3
- Isomers 3.1
- See also 4
- References 5
External links 6
- Government and organizations 6.1
- 6.2 News stories and opinion articles
History and use
The chemical was originally synthesised in 1825 by Faraday. It is named after the Dutch chemist Teunis van der Linden (1884–1965), the first to isolate and describe γ-Hexachlorcyclohexane in 1912. Its pesticidal action was discovered only in 1942, after which lindane production, by Imperial Chemical Industries Ltd (ICI), and use started up in the United Kingdom. It has been used to treat food crops and to forestry products, as a seed treatment, a soil treatment, and to treat livestock and pets. It has also been used as pharmaceutical treatment for lice and scabies, formulated as a shampoo or lotion. It is estimated that between 1950 and 2000, around 600,000 tonnes of lindane were produced globally, and the vast majority of which was used in agriculture. It has been manufactured by several countries, including the United States, China, Brazil, and several European countries, but as of 2007 only India and possibly Russia are still producing it.
By November 2006, the use of lindane had been banned in 52 countries and restricted in 33 others. Seventeen countries, including the US and Canada, allowed either limited agricultural or pharmaceutical use. In 2009, an international ban on the use of lindane in agriculture was implemented under the
- "Mom and Pros Tackle Lice" - NPR story from 2006
- Pepsi and Coca-Cola - Lindane in drinks in India - news story from 2004
- India - Pesticides in Coke & Pepsi drinks - news story from 2003
News stories and opinion articles
- FDA Information on Lindane
- EPA Information on Lindane
- Gamma Hexachlorocyclohexane Fact Sheet
- Agency for Toxics and Disease Registry: Toxicological Profile for Hexachlorocyclohexane
- Lindane in the Pesticide Properties DataBase (PPDB)
- World Health Organization Background Document on Lindane for Drinking-Water Quality Guidelines
- PAN Pesticides Database: Lindane
- Lindane Chemistry and Uses
- World Health Organization: Lindane (EHC 124)
- "Lindane Facts" - Website run by Morton Grove Pharmaceuticals
- headlice.org - Website of the National Pediculosis Association
- Michigan Ecology Center website
- Morton Grove Pharmaceuticals homepage - US producer of Lindane Medications
- U.S. National Library of Medicine: Hazardous Substances Databank – Lindane
Government and organizations
- Report of the Conference of the Parties of the Stockholm Convention on Persistent Organic Pollutants on the work of its fourth meeting. Convention on Persistent Organic Pollutants. Fourth meeting, Geneva, 4–8 May 2009. http://chm.pops.int/Portals/0/Repository/COP4/UNEP-POPS-COP.4-38.English.pdf
- Brandenberger, Hans; Maes, Robert A. A. (1997). Analytical toxicology: for clinical, forensic, and pharmaceutical chemists. Berlin: Walter de Gruyter. p. 243.
- Drugs.com Professional Drug Information: Lindane. Retrieved 2009-05-10
- Commission for Environmental Cooperation. The North American Regional Action Plan (NARAP) on Lindane and Other Hexachlorocyclohexane (HCH) Isomers. 2005. Available at: http://www.cec.org/files/PDF/POLLUTANTS/Lindane-NARAP-Public-Comment_en.pdf.
- Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services. Toxicologic profile for alpha-, beta, gamma- and delta-hexachlorocyclohenxane. August 2005. http://www.atsdr.cdc.gov/toxprofiles/tp43.pdf
- Lindane Voluntary Cancellation and RED Addendum Fact Sheet, US EPA, July name 2006.
- International Agency for Research on Cancer (IARC). Summaries & Evaluations: HEXACHLOROCYCLOHEXANES (Group 2B). Updated March 2, 1998. http://www.inchem.org/documents/iarc/suppl7/hexachlorocyclohexanes.html
- U.S. EPA. Evaluation of the Carcinogenic Potential of Lindane, PC. Code: 009001. 2001. http://www.lindane.com/pdf/EPA_Cancer_Assessment_of_Lindane2001.pdf
- World Health Organization (WHO). Lindane in Drinking Water: Background Document for Development of WHO Guidelines for Drinking-Water Quality. 2004.
- World Health Organization, The WHO Recommended Classification of Pesticides by Hazard, 2005.
- Eliane Engeler, "UN: Treaty expanded by 9 more dangerous chemicals", Associated Press 2009-05-09
- Commission for Environmental Cooperation. North American Regional Action Plan (NARAP) on lindane and other hexachlorocyclohexane (HCH) isomers. November 30, 2006. http://www.cec.org/files/PDF/POLLUTANTS/LindaneNARAP-Nov06_en.pdf
- "LINDANE: Risk Profile. UNEP/POPS/POPRC.2/17/Add.4". Stockholm Convention of Persistent Organic Pollutants.
- U.S. Environmental Protection Agency (EPA). Lindane Reregistration Eligibility Decision (RED). 2002. http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2002-0202-0027
- Report of the Conference of the Parties of the Stockholm Convention on Persistent Organic Pollutants on the work of its fourth meeting. Convention on Persistent Organic Pollutants. Fourth meeting, Geneva, 4–8 May 2009. http://chm.pops.int/Portals/0/Repository/COP4/UNEP-POPS-COP.4-38.English.pdf.
- Persistent Organic Pollutants Review Committee http://www.pops.int/documents/meetings/poprc/chemreview.htm
- Pesticide Action Network map of Lindane bans and restrictions http://www.panna.org/campaigns/docsLindane/lindaneBannedMap.pdf
- U.S. EPA. Addendum to the 2002 Lindane Reregistration Eligibility Decision (RED). July 2006. http://www.epa.gov/oppsrrd1/REDs/lindane_red_addendum.pdf
- Food and Drug Administration. Lindane Assessment Memorandum. Posted 2003. http://www.fda.gov/cder/drug/infopage/lindane/lindanememoassessment.pdf.
- McCarthy JS, Kemp DJ, Walton SF, Currie BJ (2004). "Scabies: more than just an irritation". Postgrad Med J 80 (945): 382–7.
- Thomas DR, McCarroll L, Roberts R, et al. (2006). "Surveillance of insecticide resistance in head lice using biochemical and molecular methods". Arch. Dis. Child. 91 (9): 777–8.
- FDA Public Health Advisory: Safety of Topical Lindane Products for the Treatment of Scabies and Lice. Availasble at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110845.htm
- Sciele Pharma Completes Acquisition of Alliant Pharmaceuticals. Press Release; June 12, 2007. http://phx.corporate-ir.net/phoenix.zhtml?c=120763&p=irol-newsArticle&ID=1014610&highlight
- Warning Letter from the U.S. Food and Drug Administration to Morton Grove. (undated.)
- Humphreys EH, Janssen S, Heil A, Hiatt P, Solomon G, Miller MD (March 2008). "Outcomes of the California ban on pharmaceutical lindane: clinical and ecologic impacts" (PDF). Environ. Health Perspect. 116 (3): 297–302.
- Morton Grove Pharmaceuticals, Inc. v. The National Pediculosis Association, et al., No. 06 C 3815 (N.D. Ill. June 18, 2007) (Bucklo, J.)
- Critics of drugs in for bad medicine, Laura Berman, The Detroit News, March 2, 2008.
- The Ecology Center's Clarification of Statements Regarding Lindane, Michigan Ecology Center, accessed March 3, 2008.
- Ecology Center's lindane suit settled, Art Aisner, Ann Arbor News, March 15, 2008.
- Persistent Organic Pollutant Review Committee (POPRC). Draft risk management evaluation for lindane. May, 2007. http://www.pops.int/documents/meetings/poprc/drprofile/drme/DraftRME_Lindane.pdf
- Centers for Disease Control and Prevention (CDC) (2005). "Unintentional topical lindane ingestions--United States, 1998-2003". MMWR Morb. Mortal. Wkly. Rep. 54 (21): 533–5.
- Alvarez-Pedrerol M, Ribas-Fitó N, Torrent M, et al. (2008). "Thyroid disruption at birth due to prenatal exposure to beta-hexachlorocyclohexane". Environ Int 34 (6): 737–40.
- CDC - NIOSH Pocket Guide to Chemical Hazards.
- STATE OF CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY, OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT (June 11, 2010). "CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY" (PDF). Retrieved 23 September 2010.
- World Health Organization (WHO). Lindane in Drinking Water: Background Document for Development of WHO Guidelines for Drinking-Water Quality. 2004. http://www.who.int/water_sanitation_health/dwq/chemicals/lindane/en/print.html
- Upson K, AJ De Roos, ML Thompson, S Sathyanarayana, D Scholes, DB Barr, VL Holt (2013). "Organochlorine Pesticides and Risk of Endometriosis: Findings from a Population-Based Case–Control Study". Environ Health Perspect.
- U.S. FDA Centers for Drug Evaluation and Research. Lindane lotion and lindane shampoo questions and answers. Updated April 15, 2003. http://www.fda.gov/cder/drug/infopage/lindane/lindaneQA.htm
- Lindane lotion, USP, 1% prescribing information. Updated March 28, 2003. http://www.fda.gov/cder/foi/label/2003/006309lotionlbl.pdf
- Lindane shampoo, USP, 1% prescribing information. Updated March 28, 2003. http://www.fda.gov/cder/foi/label/2003/006309shampoolbl.pdf.
- U.S. FDA. Lindane Post Marketing Safety Review. Posted 2003. http://www.fda.gov/cder/drug/infopage/lindane/lindaneaeredacted.pdf
- U.S. EPA. Assessment of lindane and other hexachlorocyclohexane isomers. February 8, 2006
- United Nations Environment Programme. POPRC of the Stockholm Convention. Draft risk profile: Lindane. July 2006.
- Life after Lindane in California: Water Concentrations, Poison Control Calls Drop Following Ban, Environmental Health Perspectives, Volume 116, Number 3, March 2008.
- International HCH & Pesticides Association. The legacy of lindane HCH isomer production. 2006. http://www.ihpa.info/docs/library/Lindane%20Main%20Report%20DEF20JAN06.pdf
- US CDC. Third National Report on Human Exposure to Environmental Chemicals. 2005. Available at: http://www.cdc.gov/ExposureReport/pdf/thirdreport.pdf.
- Kolpin DW, Furlong ET, Meyer MT, et al. (2002). "Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: A national reconnaissance". Environ Sci Technol 36 (6): 1202–1211.
- U.S. EPA. Announcement of completion of EPA's review of existing drinking water standards. Federal Register. 68(138): July 18, 2003.
- California Public Health Goal for Lindane in Drinking Water. Available at: http://oehha.ca.gov/water/phg/pdf/lindan_f.pdf.
- IPEN. Lindane: Agricultural and pharmaceutical alternatives to lindane. Available at: http://www.akaction.org/REPORTS/Alternatives%20to%20Lindane%20Report%204-29-09.pdf
Lindane is the gamma isomer of hexachlorocyclohexane ("γ-HCH"). In addition to the issue of lindane pollution, there are concerns related to the other isomers of HCH, namely alpha-HCH and beta-HCH, which are notably more toxic than lindane, lack its insecticidal properties, and are byproducts of lindane production. In the 1940s and 1950s, lindane producers stockpiled these isomers in open heaps, which led to ground and water contamination. The International HCH and Pesticide Forum has since been established to bring together experts to address the clean-up and containment of these sites. Modern manufacturing standards for lindane involve the treatment and conversion of waste isomers to less toxic industrial chemicals, a process known as "cracking." Today, only a few production plants remain active worldwide to accommodate public-health uses of lindane and declining agricultural needs. Lindane has not been manufactured in the U.S. since the mid-1970s, but continues to be imported.
Note that the EPA has set the maximum contaminant level or "MCL" for lindane allowed in public water supplies and considered safe for drinking at 200 parts per trillion (ppt). By comparison, the state of California imposes a lower MCL for lindane of 19 ppt. However, the California standard is based on a dated 1988 national water criterion that was subsequently revised by the EPA in 2003 to 980 ppt. The EPA stated that the change resulted from "significant scientific advances made in the last two decades particularly in the areas of cancer and noncancer risk assessments." While the EPA considered raising the MCL standard for lindane to 980 ppt at that time, the change was never implemented because states had little difficultly in maintaining lindane levels below the 200 ppt MCL limit already in place. Today, the legally enforceable MCL standard for lindane is 200 ppt while the national water criterion for lindane is 980 ppt.
The US EPA determined in 2002 that the Agency does not believe that lindane contaminates drinking water in excess of levels considered safe. U.S. Geological Survey teams concluded the same in 1999 and 2000. With regard to lindane medications, the EPA conducted "down-the-drain" estimates of the amount of lindane reaching public water supplies and concluded that lindane levels from pharmaceutical sources were "extremely low" and not of concern.
Over time, lindane is broken down in soil, sediment and water into less harmful substances by algae, fungi and bacteria; however, the process is relatively slow and dependent on ambient environmental conditions. The ecological impact of lindane's environmental persistence continues to be debated.
When lindane is used in agriculture, an estimated 12-30% of it volatilizes into the atmosphere, where it is subject to long-range transport and can be deposited by rainfall. Lindane in soil can leach to surface and even ground water, and can bioaccumulate in the food chain. However, biotransformation and elimination are relatively rapid when exposure is discontinued. Most exposure of the general population to lindane has resulted from agricultural uses and the intake of foods, such as produce, meats and milk, produced from treated agricultural commodities. Human exposure has decreased significantly since the cancellation of agricultural uses in 2006. Even so, the CDC published in 2005 its Third National Report on Human Exposures to Environmental Chemicals, which found no detectable amounts of lindane in human blood taken from a random sampling of about 5,000 people in the US as part of the NHANES study (National Health and Nutrition Examination Survey at: http://www.cdc.gov/nchs/nhanes/about_nhanes.htm ). The lack of detection of lindane in this large human "biomonitoring" study likely reflects the increasingly limited agricultural uses of lindane over the last two decades. The cancellation of agricultural uses in the United States will further reduce the amount of lindane introduced into the environment by more than 99%.
The production and agricultural use of lindane are the primary causes of environmental contamination, and levels of lindane in the environment have been decreasing in the U.S., consistent with decreasing agricultural usage patterns. The production of lindane generates large amounts of waste hexachlorocyclohexane isomers, and it is estimated that "every ton of lindane manufactured produces about 9 tons of toxic waste." Modern manufacturing standards for lindane involve the treatment and conversion of waste isomers to less toxic molecules, a process known as "cracking."
The black box warning emphasizes that lindane should not be used on premature infants and individuals with known uncontrolled seizure disorders, and should be used with caution in infants, children, the elderly, and individuals with other skin conditions (e.g., dermatitis, psoriasis) and people who weigh less than 110 lbs (50 kg) as they may be at risk of serious neurotoxicity.
A variety of adverse reactions to lindane pharmaceuticals have been reported, ranging from skin irritation to seizures, and, in rare instances, death. The most common side effects are burning sensations, itching, dryness and rash. While serious effects are rare and have most often resulted from misuse, adverse reactions have occurred when used properly. The FDA therefore requires a so-called black box warning on lindane products, which explains the risks of lindane products and its proper use.
Adverse reactions to lindane
In 2013, a study of women with surgically diagnosed endometriosis reported that the risk of endometriosis was positively associated with blood serum concentration of beta-Hexachlorocyclohexane (β-HCH), an isomer of lindane and byproduct of its production. Women with the highest levels of β-HCH in their blood were 30-70% more likely to have endometriosis than those with the lowest levels.
More recently, in June of 2015, the WHO published a study in the Lancet Journal of Oncology where Lindane was deemed "carcinogenic to humans", and was linked specifically to non-Hogdkin Lymphoma.
Based primarily on evidence from animal studies, most evaluations of lindane have concluded that it may possibly cause cancer. In 1987, the 
The Occupational Safety and Health Administration (OSHA) and National Institute for Occupational Safety and Health (NIOSH) have set occupational exposure limits for lindane at 0.5 mg/m3 at a time-weighted average of eight hours, for dermal exposure.
Exposure to large amounts of lindane can harm the nervous system, producing a range of symptoms from headache and dizziness to seizures, convulsions and, more rarely, death. Lindane has not been shown to affect the immune system in humans and, it is not considered to be genotoxic. Prenatal exposure to β-HCH, an isomer of lindane and production byproduct, has been associated with altered thyroid hormone levels and could affect brain development.
The EPA and WHO both classify lindane as "moderately" acutely toxic. It has an oral LD50 of 88 mg/kg in rats and a dermal LD50 of 1000 mg/kg. Most of the adverse human health effects reported for lindane have been related to agricultural uses and chronic, occupational exposure of seed-treatment workers.
Human health effects
In 2006, Morton Grove Pharmaceuticals, the sole US manufacturer of lindane pharmaceuticals, sued the National Pediculosis Association, the Michigan Ecology Center, and two physicians, alleging that they disseminated defamatory materials regarding lindane and other charges. Morton Grove alleged more than $9.3 million in damages. The defendants considered the legal action to be SLAPP suit and settled in 2008. The settlement did not require them to admit liability or make any payments to Morton Grove, but the Ecology Center did agree to clarify 7 of the statements it had published in its lindane factsheet.
Morton Grove lawsuit
The State of California banned the pharmaceutical lindane, effective 2002, and the Michigan House of Representatives passed a bill in 2009 to restrict its use to doctors' offices. A recent analysis of the California ban concluded that a majority of pediatricians had not experienced problems treating lice or scabies since that ban took effect. The study also documented a marked decrease in lindane wastewater contamination and a dramatic decline in lindane poisoning incidents reported to Poison Control Centers. The authors concluded that, "The California experience suggests elimination of pharmaceutical lindane produced environmental benefits, was associated with a reduction in reported unintentional exposures and did not adversely affect head lice and scabies treatment."
Lindane medications continue to be available in the US, though since 1995 they have been designated "second-line" treatments, meaning they can only be prescribed when other "first-line" treatments have failed or cannot be used. In December 2007, the FDA sent a Warning Letter to Morton Grove Pharmaceuticals, the sole U.S. manufacturer of lindane products, requesting that the company correct misleading information on two of its lindane websites. The letter said, in part, that the materials "are misleading in that they omit and/or minimize the most serious and important risk information associated with the use of Lindane Shampoo, particularly in pediatric patients; include a misleading dosing claim; and overstate the efficacy of Lindane Shampoo."
In the US, lindane pesticide products were regulated by the U.S. Environmental Protection Agency (EPA), while lindane medications are regulated by the Food and Drug Administration (FDA). It was registered as an agricultural insecticide in the 1940s, and as pharmaceutical in 1951. The EPA gradually began restricting its agricultural use in the 1970s due to concerns over its effects on human health and the environment. By 2002, its use was limited to seed treatments for just 6 crops, and in 2007 these last uses were canceled.
 Although the US has not ratified the Convention, it has similarly banned agricultural uses while still allowing its use a second-line lice and scabies treatment.